Semaglutide & Ozempic® Weight Loss in Kabalagala
Physician-supervised medical weight loss with Semaglutide (Ozempic® / Wegovy®) GLP-1 receptor agonist therapy. Clinically proven 15-20% average body weight loss with metabolic and cardiovascular protection.
~15-20%
Mean Body Weight Loss
STEP Clinical Trial Benchmark
88.7%
Achieved ≥5% Weight Loss
Significant Metabolic Shift
20% MACE
Cardiovascular Risk Reduction
SELECT Landmark 17,604 Trial
Once-Weekly
Subcutaneous Micro-Dose
Doctor Titrated & Monitored
What is
Semaglutide / Ozempic®?
Semaglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA) originally developed by Novo Nordisk (known internationally under the brand names Ozempic® and Wegovy®). At Refine Clinic in Kabalagala, Semaglutide is administered under strict physician guidance as a transformative medical weight-loss therapy for patients dealing with obesity, metabolic syndrome, or stubborn weight plateaus.
Hypothalamic Appetite & "Food Noise" Suppression
Semaglutide crosses into the central nervous system to target the hypothalamus, turning down constant food cravings, emotional snacking impulses, and chronic hunger signals.
Delayed Gastric Emptying
Slows the rate at which food leaves the stomach, prolonging post-meal satiety and fullness so smaller, nutrient-dense portions satisfy you completely for hours.
Insulin Sensitivity & Cardiovascular Protection
Stimulates glucose-dependent insulin secretion, suppresses glucagon, dramatically improves HbA1c, and delivers a clinically proven 20% reduction in major adverse cardiac events.
Weekly Micro-Injection Protocol
Gradual Dose Escalation for Maximum Comfort
Novo Nordisk Scientific Standard
Administered by Medical Aesthetic Doctors & Certified Nutritionists
Genuine GLP-1 Medicines & Formulations Available
Refine Skin and Body Clinic provides 100% authentic, temperature-controlled Novo Nordisk® medications. Explore the full range of injectable pens and oral tablet formulations prescribed under doctor supervision in Kabalagala.
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is a prescription medicine indicated:
- Glycemic Control: Along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.
- Cardiovascular Defense: To reduce the risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with type 2 diabetes and known heart disease.
- Kidney Disease Protection: To reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
Ozempic® (semaglutide) tablets 4 mg or 9 mg are prescription medicines indicated:
- Glycemic Control: Along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.
- Cardiovascular Risk Reduction: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes who are at high risk.
- Oral Bioavailability Protocol: Taken first thing in the morning with a sip of plain water (up to 4 oz) at least 30 minutes before any food, drink, or other medications.
Wegovy® (semaglutide) injection is a prescription medicine used with a reduced-calorie diet and increased physical activity to:
- Weight Reduction & Maintenance: Help adults with obesity (BMI ≥30), or excess weight (BMI ≥27) who also have weight-related medical problems, lose weight and keep the weight off permanently (~15-20% average total weight loss).
- SELECT Cardiovascular Trial: Reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
- Pediatric Indication: Approved to reduce excess body weight and sustain weight reduction in pediatric patients 12 years and older with obesity.
Wegovy® (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to:
- Non-Injectable Weight Loss: Deliver profound satiety, crave reduction, and significant body weight loss (up to 15.1% mean reduction in OASIS-1) for needle-averse patients.
- Cardiovascular Protection: Reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and overweight/obesity.
- Consistent Daily Rhythm: Once-daily oral formulation that eliminates the need for self-injections and cold-chain travel concerns once opened.
Oral GLP-1
RYBELSUS® (semaglutide) tablets 7 mg & 14 mg
The original FDA-approved daily oral GLP-1 receptor agonist for glycemic optimization, moderate weight loss, and appetite modulation without needles.
Daily GLP-1 Pen
Saxenda® (liraglutide) injection 3 mg
Once-daily subcutaneous injection indicated for chronic weight management in adults (BMI ≥30 or ≥27 with risk factors) and adolescents aged 12-17.
Choosing the Right Formulation for Your Body
Dr. Chirag Kotecha evaluates your medical history, metabolic baseline, and lifestyle to determine the exact optimal GLP-1 formulation.
| Formulation | Active Molecule | Route & Frequency | Target Indication | Clinical Weight Loss | Delivery Method |
|---|---|---|---|---|---|
| Ozempic® Injection | Semaglutide | Once Weekly Subcutaneous | Type 2 Diabetes, CV Defense, Kidney Protection | Up to ~15% TBWL | Pre-filled Multi-Dose Pen (32G micro-needle) |
| Ozempic® Tablets | Semaglutide | Once Daily Oral (Fasting) | Glycemic Control & High CV Risk Reduction | Up to ~10-12% TBWL | Oral Tablet (with up to 4 oz plain water) |
| Wegovy® Injection | Semaglutide (High Dose) | Once Weekly Subcutaneous | Chronic Weight Management (Obesity / Overweight) + CV | ~15% – 20% TBWL (STEP-1) | Pre-filled Single-Dose Auto-Injector Pen |
| Wegovy® Tablets | Semaglutide (25 mg) | Once Daily Oral (Fasting) | Oral Chronic Weight Management (Needle-Free) | Up to ~15.1% TBWL (OASIS-1) | Oral Tablet in moisture-sealed bottle |
| RYBELSUS® | Semaglutide | Once Daily Oral | Type 2 Diabetes Glycemic Control & Moderate Satiety | ~8% – 10% TBWL | Oral Tablet (SNAC enhanced carrier) |
| Saxenda® | Liraglutide | Once Daily Subcutaneous | Chronic Weight Management (Adults & Adolescents 12+) | ~8% – 10% TBWL | FlexTouch® Daily Dial-a-Dose Pen |
Cold-Chain Guaranteed
Continuous 2°C–8°C storage monitoring to preserve delicate peptide integrity.
Authentic Batch Verification
100% genuine Novo Nordisk® serialized packs directly sourced from verified distributors.
Physician Oversight
Personalized dosing titration, lab biomarker monitoring, and nutritionist meal coaching.
Real Transformations & Documented Progress
Explore documented weight loss milestones from patients undergoing physician-supervised medical weight management at Refine Clinic.
-21.0 kg (-3.3 Stone)
Dot • 12-Week Milestone
Visceral Belly Fat & Waist Contour
"Before starting, food noise and evening cravings ruled my days. Within 2 weeks of clinical dosing, I felt comfortably in control. Losing 21 kg completely restored my energy and health."
-20.3 kg (-3.2 Stone)
Jacques • 6-Month Program
Pre-Diabetes Reversal & Liver Fat
"My blood sugar had crept into pre-diabetic territory and blood pressure was high. Under Dr. Chirag's protocol, I shed over 20 kg, dropped my HbA1c to normal, and feel 15 years younger."
-17.2 kg (-2.7 Stone)
Georgie • 16-Week Program
Postpartum Weight Reset
"Post-baby weight wouldn't budge no matter how much cardio I did. Semaglutide paired with Refine Clinic's nutrition guidance broke through my plateau without extreme starvation."
A Full Metabolic Lifestyle Reset
At Refine Clinic, weight loss is never just about handing you a prescription. Our medical team pairs GLP-1 therapy with lean muscle preservation protocols (including optional Wonder® Axon body sculpting), continuous dietary coaching by certified nutritionist Wendy Emyedu Ayayo, and regular blood biomarker checks to ensure your results stay permanent.
Our 4-Step Weight Loss Journey
Designed by Dr. Chirag Kotecha to guarantee patient safety, minimize gastrointestinal adjustment side effects, and optimize steady fat reduction.
Comprehensive Evaluation
Full physician consultation including BMI assessment, blood pressure, fasting lipid panel, liver/kidney function tests, and personal/family health history.
Micro-Dose Initiation
Begin with a low introductory dose (0.25 mg weekly) to gently introduce your gastrointestinal system to GLP-1 signaling while avoiding nausea.
Monthly Titration
Dosing is systematically escalated (0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg) on a 4-week cycle based on your personal tolerance and weight-loss rate.
Long-Term Maintenance
Once goal weight is achieved, our medical team transitions you to a customized maintenance strategy or tapering program to permanently prevent weight regain.
Novo Nordisk Dose Escalation Schedule
Semaglutide requires careful, structured dose titration to prevent gastrointestinal upset and build sustained metabolic tolerance.
| Phase | Timeline | Weekly Subcutaneous Dose | Clinical Objective | Patient Experience |
|---|---|---|---|---|
| Initiation Phase | Weeks 1 – 4 | 0.25 mg / week | Gastrointestinal tolerance and baseline receptor binding | Mild craving suppression, steady hunger reduction |
| Step-Up Phase | Weeks 5 – 8 | 0.50 mg / week | Active weight reduction onset and glycemic stabilization | Significant drop in portion sizes, reduced snacking |
| Therapeutic Phase | Weeks 9 – 12 | 1.0 mg / week | Substantial fat loss acceleration and metabolic reset | Rapid visceral fat clearance, clothes fitting noticeably looser |
| Escalation Phase | Weeks 13 – 16 | 1.7 mg / week | Continued deep lipolysis for patients requiring higher control | High satiety, elimination of food obsession |
| Full Maintenance Phase | Week 17+ Ongoing | 2.4 mg / week | Full STEP trial dose for maximum weight loss & MACE cardiac defense | Peak physical transformation, up to 15-20% TBWL sustained |
Dr. Chirag Kotecha
Refine Skin & Body Clinic • Kampala, Uganda
"Semaglutide is a powerful medical molecule that should never be purchased from unverified online vendors or administered without clinical lab monitoring. At Refine, our strict safety protocol screens out contraindications, balances thyroid health, and ensures authentic, temperature-controlled medication."
Important Safety Information & Contraindications
- Thyroid C-Cell Tumor Risk: Semaglutide is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Pancreatitis: Patients with a history of acute pancreatitis should not use GLP-1 receptor agonists without prior specialist medical clearance.
- Pregnancy & Breastfeeding: Discontinue medication at least 2 months before a planned pregnancy. Not approved for nursing mothers.
- Managing Mild Side Effects: Nausea, acid reflux, or constipation are typically mild and transient during dose escalation. Our medical team prescribes hydration protocols and anti-emetics when needed.
Frequently Asked Questions
Everything you need to know about Semaglutide (Ozempic/Wegovy) treatment at Refine Clinic.
1. What is the difference between Ozempic® and Wegovy®?
2. How much weight can I expect to lose on Semaglutide?
3. Are both injection pens and oral tablets available at Refine Clinic?
4. How is the injection pen administered? Does it hurt?
5. Can I combine Semaglutide with Wonder® Axon body sculpting?
6. What happens when I reach my target weight? Will I regain the weight?
7. Where are Refine Clinic locations in Uganda and Juba?
- HQ Forest Mall: First Floor, Lugogo Bypass, Kampala (+256 703 898 904)
- Kabalagala Branch: Palm Village Mall, 2nd Floor (+256 705 035 096)
- Bukoto Branch: UMC Victoria Hospital Annex (+256 748 951 996)
- Juba Branch: 1st Floor, Sadeco Building, Airport Road, South Sudan (+211 922 687 111)
Begin Your Semaglutide Weight Loss Program
Schedule your confidential medical consultation with Dr. Chirag Kotecha at Refine Clinic.